We chose Oracle Healthcare Transaction Base because it complies with the worldwide HL7 standard for clinical data, and because it comes from a major international company, committed to supporting, developing, and refining the product over time. When we conducted a market evaluation, Oracle also came in at the right price. – Jack Robinson, IT Manager, Stockholm County CouncilIn an article entitled "Missarna som knäckte GVD" (roughly: Flaws in the Cracked GVD"), Madeleine Bäck reports on the recent history of the GVD project, which continues to move from crisis to crisis:
Heavy criticism is directed towards the choice of storage system for GVD, the so-called HTB database, which was acquired from WM-Data and its partner Oracle in 2004. 'Our pilot tests point to catastrophic performance when loading data to the system. We also observed that it would be incredibly complicated and expensive to adapt HTB to the GVD', explains one involved person (who however chose to remain anonymous). The suppliers who built the GVD are aware of the criticism, but they do not agree with all aspects: Pia Kullstrom, head of Public Sector and Healthcare at WM-Data, pushes back specifically as regards criticism of the HTB system. This is not based on facts she claims, but rather on people having a different product-religion.
I am told that features of the GVD marked out as problematic include:
1. The poorly functioning BAT&Portal (for authentication and authorisation services), which uses HL7's CCOW (Clinical Context Object Workgroup) standard protocol, and is supposed to be a web-based, single point of entry and single sign-on access route to the different parts of the system.As a whole, GVD is a classical "big bang" project, where the thinking has been quantitative, not qualitative, and the Stockholm political leadership has admitted that GVD is an "IT-fiasco".
2. For writing data to HTB the performance is 'still horrendous', even though Oracle re-wrote the whole implementation for reading data through their API after Stockholm had already accepted the HTB product.
3. GVD has a strongly centralized architecture, but its protagonists did not address the question of how to handle the legacy systems during the transition period. Many of the latter are fully functional, mission critical, clinical systems. Centralized architectures, in which the attempt is made to consolidate semantically non-interoperable data from hundreds of databases into one, are show-stoppers.
But the responsible civil servants remain in denial, and there have not as yet been any signals to the effect that they are going to back down from HTB. This raises one further problem: GVD has Oracle HTB, and thus HL7 V3, as central component. One can state with high confidence that HL7 V3 is not going to be the standard at national level for interchange of clinical data in Sweden. So what is Stockholm going to do?